🇺🇸 ER-niacin in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 10

Most-reported reactions

1. Alanine Aminotransferase Increased — 1 report (10%)
2. Anaemia — 1 report (10%)
3. Aspartate Aminotransferase Increased — 1 report (10%)
4. Blood Alkaline Phosphatase Increased — 1 report (10%)
5. Dehydration — 1 report (10%)
6. Diarrhoea — 1 report (10%)
7. Liver Function Test Increased — 1 report (10%)
8. Peripheral T-Cell Lymphoma Unspecified — 1 report (10%)
9. Sinus Disorder — 1 report (10%)
10. Syncope — 1 report (10%)

Source database →

Frequently asked questions

Is ER-niacin approved in United States?

ER-niacin does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for ER-niacin in United States?

Merck Sharp & Dohme LLC is the originator. The local marketing authorisation holder may differ — check the official source linked above.